Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Veracyte Q4 Earnings Preview


Veracyte (NASDAQ: VCYT) announces its next round of earnings this Monday, Feb. 25. Here's Benzinga's advanced look at Veracyte's Q4 earnings report.

Earnings and Revenue

Sell-side analysts are expecting Veracyte's loss per share to be near 15 cents on sales of $24.36 million.

In the same quarter last year, Veracyte announced an EPS loss of 24 cents on revenue of $19.5 million. Revenue would be up 24.31 percent from the year-ago period. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:


Quarter Q3 2018 Q2 2018 Q1 2018 Q4 2017
EPS Estimate -0.25 -0.27   -0.2
EPS Actual -0.12 -0.18 -0.27 -0.24

Stock Performance

Over the last 52-week period, shares are up 245.26 percent. Given that these returns are generally positive, long-term shareholders are probably happy going into this earnings release.

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The most common rating by analysts on Veracyte stock is a Neutral. The strength of this rating has maintained conviction over the past three months.

Posted-In: Earnings News


Related Articles (VCYT)

View Comments and Join the Discussion!

US Xpress Showcases Driver Simulator At 2019 LINK Conference

AstraZeneca's Brilinta Found To Alleviate Cardiovascular Risk In Late-Stage Study